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OBJECTIVES: To determine the effect of Helicobacter pylori (H. pylori) eradication on blood levels of high-sensitivity
C-reactive protein (hs-CRP), macrophage migration inhibitory factor and fetuin-A in patients with dyspepsia who
are concurrently infected with H. pylori.
METHODS: H.pylori infection was diagnosed based on the
14C urea breath test (UBT) and histology. Lansoprazole
30 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily were given to all infected
patients for 14 days;
14C UBT was then re-measured. In 30 subjects, migration inhibitory factor, fetuin-A and hs-CRP
levels were examined before and after the eradication of H. pylori infection and compared to levels in 30 healthy
subjects who tested negative for H. pylori infection.
RESULTS: Age and sex distribution were comparable between patients and controls. Migration inhibitory factor and
hs-CRP levels were higher, and fetuin-A levels were lower, in H. pylori-infected patients (p,0.05). Following
eradication of H. pylori, migration inhibitory factor and hs-CRP levels were significantly decreased, whereas fetuin-A
levels were increased. However, eradication of the organism did not change lipid levels (p.0.05).
CONCLUSION: These findings suggest that H. pylori eradication reduces the levels of pro-inflammatory cytokines
such as migration inhibitory factor and hs-CRP and also results in a significant increase in anti-inflammatory markers
such as fetuin-A.
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C-reactive protein.
Kebapcilar L, Bilgir O, Cetinkaya E, Akyol M, Bilgir F, Bozkaya G. The effecto fhelicobacter pylori eradication on macrophage migration inhibitory
factor, c-reactive protein and fetuin-a levels. Clinics. 2010;65(8):799-802.
Received for publication on April 12, 2010; First review publication on May 18, 2010; Accepted for publication on May 25, 2010
E-mail: leventkebapcilar@yahoo.com
Tel.: 00 90 2223505050-4082
INTRODUCTION
Several epidemiologic studies have suggested associa-
tions between H. pylori seropositivity and atherosclerosis.
1
Atherosclerosis is defined as a metabolic and inflammatory
disease, and several inflammatory and immunologic factors
have been established to significantly contribute to ather-
ogenesis. Both humoral and cellular immune mechanisms
play a major role in the onset and/or progression of
atheromatous lesions.
2 MIF is an important cytokine that
regulates both adaptive and immune responses.
3 It is a
potent pro-inflammatory cytokine that has been reported to
stimulate TNF and IL-6 expression
4 and an important
downstream marker of inflammation. C-reactive protein
(CRP) is one of the acute phase proteins that increase during
systemic inflammation.
5,6 It has also been reported that
measurement of serum levels of CRP using a high-
sensitivity assay (hs-CRP) can reveal subclinical inflamma-
tory states that may reflect vascular inflammation.
7
Anti-inflammatory cytokines produced during inflamma-
tion tend to modulate the inflammatory reaction. One
cytokine, fetuin-A, is considered to be a potent anti-
inflammatory cytokine. Fetuin-A is an anti-inflammatory
mediator that participates in macrophage deactivation,
8
anti-fibrotic activity,
9 and inhibition of apoptosis in vascular
smooth muscle cells.
10
Although anti-inflammatory markers appear to have
beneficial effects and decrease the risk of cardiovascular
events, little is known about the effect of H. pylori eradica-
tion on inflammatory and anti-inflammatory markers of
atherosclerosis. In this study, we determined the effect of
H. pylori eradication on blood levels of MIF and fetuin-A in
patients with dyspepsia in comparison to the levels in non-
infected healthy subjects.
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Subjects with dyspepsia symptoms who visited an inter-
nal medicine outpatient clinic were included in the study.
Subjects with hypertension (HTN), diabetes mellitus (DM),
known coronary artery disease, coagulation abnormalities,
cerebrovascular disease, renal disease, rheumatoid arthritis,
cancer, systemic or local infection, prior history of gastric
surgery, smoking, and pregnant or lactating women were
excluded. In addition, patients were excluded if they had
used supplemental vitamins, statins, warfarin, antibiotics,
nonsteroidal antiinflammatory drugs (NSAIDs), bismuth
salts, or H2-receptor blockers and proton-pump inhibitors
within 4 weeks prior to the study.
H. pylori was considered to be present when the
14C urea
breath test (
14C UBT) and histological examination were
positive. There were initially 62 patients with dyspeptic
symptoms included in the study. After the administration of
14C UBT, 11 subjects negative for H. pylori were excluded.
The remaining 51 patients underwent endoscopy, and 5 of
these subjects were excluded due to negative histology.
Triple eradication therapy was given for 14 days to the
remaining 46 patients positive both for
14C UBT and
histology. An additional 16 subjects were excluded from
the study due to positive results on the repeated
14C UBT.
Thus, H. pylori infection was successfully eradicated in 30
subjects. MIF, fetuin-A, and hs-CRP levels were studied
before and after the treatment and compared to levels in 30
healthy H. pylori-negative subjects who presented for only a
routine check-up and had no other complaints, known
chronic disease, or known medication use. The control
subjects were considered to be H. pylori-negative if a rapid
urease test was negative. This study was carried out
between July 2008 and September 2009. Written informed
consent was obtained from each subject, and research
protocols were approved by the Ethical Committee of our
institution.
14C urea breath test
After fasting overnight, patients swallowed 37 kBq (1 mCi)
of an encapsulated form of
14C-urea/citric acid composition
(Helicap
TMNoster System, Stockholm, Sweden) in 25 ml




System) after 10 min. Patients exhaled gently into the
cartridge mouthpiece until the indicator membrane changed
color from orange to yellow. The BreathCard was inserted
into a special small desktop Geiger–Mu ¨ller counter
(Heliprobe
TM Analyzer; Noster System) and activity was
counted for 250 s. Results were expressed both as counts per
min (cpm) and as a grade (0: not infected and ,25 cpm; 1:
equivocal and 25–50 cpm; 2: infected and . 50 cpm) as
suggested by the manufacturer and according to the counts
obtained from the cartridges.
Endoscopy and histology. After fasting overnight,
esophago-gastro-duodenoscopy was performed with an
Olympus videoscope. Two biopsy specimens were
obtained from the corpus and the antrum of the stomach.
Biopsies were processed separately for histological
examination according to a standard procedure, and
hematoxylin and eosin staining and Giemsa staining were
performed on these samples. A pathologist examined
samples for active and chronic H. pylori infection.
Eradication regimen. Lansoprazole 30 mg twice daily,
amoxicillin 1 g twice daily, and clarithromycin 500 mg twice
daily were given for 14 days to all infected patients.
Laboratory Evaluation. Following an overnight fasting,
venous blood samples were collected in the morning (8:00–
9:00 A.M) for laboratory measurements. Blood samples
for the measurement of fetuin-A, hs-CRP and MIF were
evaluated in patients before and after eradication. Serum
samples were stored at 270 ˚C until analysis. Serum hs-CRP
was determined using a commercially available sandwich
ELISA kit (DRG International, USA) and serum MIF levels
were measured with a quantitative sandwich human MIF
ELISA (R&D Systems, USA) using a monoclonal antibody
against MIF. Serum concentrations of fetuin-A were
measured using a human fetuin-A ELISA kit (BioVendor
Laboratory Medicine Inc., Brno, Czech Republic). Total
Cholesterol, Tg, HDL, LDL, glucose levels were determined
using routine laboratory techniques.
Statistical analysis
The results are presented as means ¡ SD. The
Kolmogorov-Smirnov test was used to determine whether
continuous variables were normally distributed. According
to the KS test, all variables including age, BMI, lipid
parameters, and concentrations of hs-CRP, fetuin-A and
MIF showed a normal distribution. Student’s t-test was used
for the comparison of continuous variables. Differences
between categorical variables were analyzed by Fisher’s
exacttest.Apairedsamplet-testwasusedforthecomparison
of treatment effects on variables. The statistical analysis was
carried out using Statistical Package for Social Sciences
(SPSS), version 13.0 (SPSS Inc., Chicago, IL). A p-value of
,0.05 was considered to be statistically significant.
RESULTS
The study group consisted of 30 H. pylori-infected patients
(29.1 ¡ 7.5 years, 23.0 ¡ 4.5 kg/m
2) and 30 control subjects
(29.1 ¡ 5.8 years, 23.7 ¡ 3.1kg/m
2). When compared to
controls, H. pylori-infected patients had significantly higher
concentrations of hs-CRP (0.90 ¡ 0.88 vs. 0.52 ¡ 0.27 mg/L,
P =0.028) and MIF (8.5 ¡ 2.4 vs 5.1 ¡ 1.5 ng/mL, P ,0.001)
as well as significantly lower fetuin-A levels (28.7 ¡ 7.7 vs
50.1 ¡ 20.9 ng/mL, P ,0.001). No statistically significant
difference was observed for BMI, lipid levels, fasting
glucose levels, and age between H. pylori-infected patients
and healthy controls (Table 1). Following eradication
of H. pylori, MIF and hs-CRP concentrations decreased
significantly (8.5 ¡ 2.4 vs 6.5 ¡ 1.8 ng/mL, P ,0.001 and
0.90 ¡ 0.88 vs. 0.63 ¡ 0.55 mg/L, P=0.004, respectively).
However, the lipid levels and BMI were not different
following eradication (P.0.05). H. pylori eradication was
associated with a progressive increase in serum fetuin-A
levels (28.7 ¡ 7.7 vs 36. 8¡ 16.9 ng/mL, P=0.007).
Pearson’s correlation analysis showed that prior to eradica-
tion, MIF levels were significantly and negatively correlated
with those of fetuin-A (Fig 1: r= 20.4, P =0.002).
DISCUSSION
In this study, we found that MIF and hs-CRP levels were
significantly increased and fetuin-A levels were signifi-
cantly decreased in H. pylori-infected patients when com-
pared to control subjects. Eradication of H. pylori was
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800significantly associated with increased levels of fetuin-A
and reduced levels of MIF and hs-CRP in patients free of
classic cardiovascular (CV) risk factors. However, eradica-
tion of the microorganism had no effect on the lipid profile.
Inflammation is a common feature of all stages of
atherosclerosis. However, conflicting results regarding the
relationship between H. pylori infection and atherosclerosis
have been reported. Although various studies have inves-
tigated the potential correlation between H. pylori infection
and ischemic heart disease (IHD), several epidemiological
studies have not shown any clear correlation between
H. pylori infection and IHD.
Recent studies have focused on the effect of H. pylori
infection on hs-CRP levels.
11,12 In recent studies, serum
levels of hs-CRP were higher in H. pylori-infected patients
than in non-infected healthy control groups. It was
previously demonstrated that serum levels of hs-CRP were
significantly reduced in most H. pylori-infected patients after
successful eradication of H. pylori.
13 These findings are
in agreement with the results of our study, which showed
that hs-CRP production was significantly reduced after
eradication of H. pylori, implying a beneficial effect in
decreasing systemic inflammation.
MIF levels were higher in H. pylori-infected patients than
in healthy controls. Recently, two reports showed that MIF
production was increased during H. pylori infection.
14,15
However, to our knowledge, no report in the literature has
examined the effect of treatment on MIF levels in H. pylori-
infected patients. In this study, we demonstrated that the
eradication of the offending microorganism was associated
with significantly decreased MIF levels. MIF is a key
proinflammatory mediator that plays a pivotal role in
inflammatory and immune diseases. It has been demon-
strated that MIF increases inflammatory responses includ-
ing the levels of cytokines such as IL-1, IL-6, IL-8, and TNF-
a; it also increases proliferative responses in many cell types
by inducing the NF-kB, Erk1/2, and AP-1 signaling path-
ways




via various mechanisms: leukocyte recruitment and arrest
via its chemokine-like functions, macrophage activation and
production of proinflammatory cytokines, foam cell forma-
tion, and processes of cell proliferation and anti-apoptosis.
23
MIF inhibition has been shown to induce the stabilization
and even regression of atherosclerotic plaques.
22 Based on
these observations, H. pylori eradication may exert a
beneficial effect by decreasing the MIF upregulation that
occurs in this infection.
In contrast, fetuin-A is an anti-inflammatory mediator
that participates in macrophage deactivation. Specifically,
fetuin-A enhances the cellular uptake of cationic inhibitors
of pro-inflammatory cytokine synthesis by macrophages,
thus preventing the morbid sequelae of infection that result
from overproduction of pro-inflammatory cytokines.
24-26
Accumulating evidence shows that low fetuin-A concentra-
tions are related to increased cardiovascular mortality.
27-29
To our knowledge, there is no report in the literature about
fetuin-A levels and the effect of treatment in H. pylori-
infected patients. Serum fetuin-A levels decrease with
H. pylori infection and our investigation showed that
eradication of the offending microorganism was associated
with significantly increased fetuin-A levels.
This study demonstrates beneficial effects of H. pylori
eradication on markers of low-grade inflammation, i.e.,
decreased MIF and hs-CRP levels and increased fetuin-A
levels, in patients free of cardiovascular risk factors. There is
a need for large interventional randomized studies to prove
an association between Helicobacter pylori seropositivity and
atherosclerosis.
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